Treat

• NanoViricides will begin a Phase II clinical trial next week for NV-387, an oral gummy drug designed to treat the Bundibugyo Ebola virus. • The trial responds to an expanding outbreak in the Democratic Republic of Congo where the crude fatality rate has reached 48%. • A successful treatment could reduce deaths and slow the spread of the virus during the largest outbreak currently affecting the region.

• The Food and Drug Administration is seeking public input on the potential for supervised therapeutic use of psychedelic drugs. • Current federal laws classify hallucinogens like psilocybin and MDMA as Schedule I drugs, meaning they are legally defined as having no accepted medical use. • This classification creates bureaucratic red tape that makes medical research into these treatments slow and difficult for scientists.

• NanoViricides will begin a clinical trial next week for the oral drug NV-387 to treat an expanding Ebola outbreak in the Democratic Republic of Congo. • The current outbreak of the Bundibugyo Ebolavirus variant has a 48% crude fatality rate and no approved treatment or vaccine. • The virus has spread into displacement camps hosting over 4.4 million people, creating a high-risk population with poor sanitation and medical resources.

• Clinical trials for the oral drug NV-387 will begin to treat a rapidly expanding outbreak of the Bundibugyo Ebolavirus in the Democratic Republic of the Congo. • The virus has spread into displacement camps hosting over 4.4 million people who lack adequate drinking water, sanitation, and medical resources. • This trial is critical because there is currently no approved treatment or vaccine for this specific variant of the Ebolavirus Disease.

• India's market regulator, Sebi, is considering weakening or abandoning its recent market-closing auction reform after facing investor backlash and volatility. • The reform was originally designed to curb price manipulation during the final minutes of trading. • A retreat from this policy highlights systemic issues for traders, including high securities taxes, shallow liquidity, and restrictions on short selling.

• The Euro fell below 1.1600 against the US Dollar on Friday as the initial market reaction to a European Central Bank interest rate hike faded. • Traders are shifting focus toward the upcoming Consumer Price Index (CPI) release from the US Department of Labor Statistics. • This currency shift affects international trade costs and investment returns for professionals managing assets in both Euro and Dollar denominations.

• EU foreign policy chief Kaja Kallas recently told The Irish Times that the European Union should treat Israeli settlements similarly to Russian-occupied Crimea. • Kallas argued that implementing an EU-wide trade ban on goods from these occupied territories would be a principled stand. • France announced this week it will pursue a national trade ban, joining the UK, Canada, Spain, the Netherlands, Belgium, and Ireland.

• Asian stock markets declined on Thursday following a retreat on Wall Street and rising energy costs. • Crude oil prices traded above $100 a barrel while Hong Kong's Hang Seng index fell 1.5% to 24,909.58. • High oil prices and falling shares create volatility for global investors and increase operational costs for businesses.

• NanoViricides announced on September 8, 2026, that it has registered a Phase II clinical trial for NV-387 oral gummies to treat the Bundibugyo ebolavirus outbreak in the Democratic Republic of Congo. • The company reports that NV-387 previously performed better than the drug Remdesivir in a lethal animal model of a viral disease. • This trial addresses a critical gap in healthcare because there is currently no approved vaccine or treatment for the specific strain of ebolavirus causing the expanding outbreak.

• NanoViricides announced on September 8, 2026, that it registered a Phase II clinical trial for NV-387 oral gummies to treat the Bundibugyo Ebola virus. • The trial is listed in the Pan African Clinical Trials Database to address the expanding Ebola outbreak in the Democratic Republic of Congo. • This development provides a potential oral treatment option for patients in a region currently facing the largest Ebola outbreak on record.